81.36
+1.11(+1.38%)
Currency In USD
Address
7707 Gateway Boulevard
Newark, CA 94560-1160
United States of America
Phone
510 474 0170
Sector
Healthcare
Industry
Biotechnology
Employees
124
First IPO Date
August 11, 2016
| Name | Title | Pay | Year Born |
| Dinesh V. Patel | Chief Executive Officer, President, Secretary & Director | 1.37M | 1957 |
| Asif Ali | Executive VP & CFO | 805,042 | 1974 |
| Suneel K. Gupta | Executive Vice President of Clinical Development | 896,847 | 1958 |
| Arturo Molina | Chief Medical Officer | 956,912 | 1959 |
| Ashok Bhandari | EVP & Chief Discovery Officer | 0 | 1964 |
| Newman Yeilding | Executive VP, Chief Scientific Officer | 0 | N/A |
| Carter J. King | Executive Vice President of Business Development | 0 | 1971 |
| Matthew Gosling | Executive VP and Chief Legal & Business Officer | 0 | 1971 |
| Mohammad Masjedizadeh | Executive VP & CTO | 0 | N/A |
| Carena Spivey | Senior Vice President & Chief Human Resources Officer | 0 | N/A |
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.